What’s Next
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Results from Pioneer: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis.
Akin C, Elberink HO, Gotlib J, et al. American Society of Hematology Virtual Conference; December 5-8, 2020. Abstract 1248.
Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
Giannetti MP, Akin C, Hufdhi R, et al. J Allergy Clin Immunol. 2021;147(4):1497-1501.e1491.
Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: results of the TouchStone SM Patient Survey.
Mesa RA, Sullivan EM, Dubinski D, et al. Cancer. 2022; 128(20): 3691-3699.
Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey.
Mesa RA, Sullivan EM, Dubinski D, et al. Cancer. 2022;128(20):3700-3708.
Systemic mastocytosis: molecular landscape and implications for treatment.
Monaldi C, De Santis S, Mancini M, et al. Mediterr J Hematol Infect Dis. 2021;13(1):e2021046.
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A. Am J Hematol. 2021;96(4):508-525.
Personalized management strategies in mast cell disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
Valent P, et al. J Allergy Clin Immunol. 2022;10(8):1999-2012.
Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial.
van Anrooij B, Oude Elberink JNG, Span LFR, et al. J Allergy Clin Immunol. 2018;142(3):1006-1008.
Systemic mastocytosis: multidisciplinary approach.
Zanotti R, Tanasi I, Crosera L, et al. Mediterr J Hematol Infect Dis. 2021;13(1):e2021068.
Clinical Practice Guidelines
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Arber DA, Orazi A, Hasserjian R, et al. Blood. 2016;127(20):2391-2405.
NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis.
National Comprehensive Cancer Network.
Patient Resources
The Mast Cell Disease Society, Inc. (TMS)
TMS is dedicated to providing multifaceted support to patients, families, and medical professionals in the community and to leading the advancement of knowledge and research in mast cell diseases through education, advocacy, and collaboration.
The European Competence Network on Mastocytosis (ECNM)
The goal of the ECNM is to improve disease-recognition, diagnosis, and therapy in patients with mastocytosis in Europe.
National Organization for Rare Disorders (NORD)
NORD is a patient advocacy organization committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
What’s Next: Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
| Faculty: | Anne L. Maitland, MD, PhD |
| Release: | 11/30/2022 |
| Expiration: | 11/30/2023 |
